Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics as Adjuvant Treatment for Bacterial Vaginosis
NCT03894813Phase 4Completed
- Sponsor
- Peking University Shenzhen Hospital
- Start
- Mar 2019
- Primary completion
- Dec 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Umeta-Miyue in bacterial vaginosis (BV) (2 arms), sponsored by Peking University Shenzhen Hospital. Primary endpoints: Number of Participants With Related Clinical Signs or Symptoms at Baseline, Number of Participants With Clinically Effective in Each Study Arm at 90 days and 1 more. Started Mar 2019; status: completed.
02
Drugs
Umeta-Miyue
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT03894813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03894813.